Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.

Also called NCT01365481

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 150 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01365481
  • EudraCT 2009-017594-37
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Colombia, Finland, Germany, Guatemala, Philippines, Poland, Romania, Russia, Singapore, South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01365481. Allocation not applicable; no masking; primary purpose treatment. Start 2011-08 (registry gives no type); primary completion 2015-09 (actual). Results posted on 2016-04-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age
Condition
Hypertension
Intervention (Drug)
Valsartan
Intervention (Drug)
amlodipine
Intervention (Drug)
Hydrochlorothiazide
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01365481
Content hash
a1308fabea31a443b3ddaf991efced5a5ca4fd1273d41f88198a3ab7e8012e9e